Replacing the phthalimide core in thalidomide with benzotriazole

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Proteolysis-targeting chimaeras (PROTACs) require novel ligands for E3 ligase recruitment.
• Traditional immunomodulatory drugs (IMiDs) like thalidomide bind to Cereblon (CRBN), a substrate receptor for the CRL4A E3 ligase.
• Developing new CRBN ligands is crucial for advancing PROTAC technology.

Purpose of the Study:

• To design and synthesize a novel thalidomide analogue with a modified core structure.
• To investigate the binding properties and cellular activity of the new analogue compared to thalidomide.
• To explore the potential of benzotriazole-containing compounds as CRBN ligands for PROTAC applications.

Main Methods:

• Innovative synthetic strategy to replace the phthalimide moiety of thalidomide with benzotriazole.
• Crystallographic analysis to determine the binding mode of the novel analogue.
• Biophysical assays (e.g., affinity assays) to quantify binding strength.
• Cell-based assays to evaluate cellular effects and properties.

Main Results:

• Successful synthesis of a benzotriazole-based thalidomide analogue.
• Crystallographic data revealed a similar binding mode to Cereblon compared to thalidomide.
• Affinity assays and cell culture experiments demonstrated improved properties of the novel compound.
• The benzotriazole moiety effectively replaces the phthalimide core while retaining CRBN interaction.

Conclusions:

• The designed benzotriazole analogue represents a promising new class of ligands for Cereblon.
• This finding expands the chemical space for developing novel E3 ligase binders for PROTACs.
• The improved properties suggest potential therapeutic advantages over traditional IMiDs.